Oramed Pharmaceuticals Overview
Oramed Pharmaceuticals has developed a proprietary platform technology that allows for the oral delivery of drugs currently administered only via injection. The company's flagship product is an oral insulin capsule that has the potential to better the lives of millions of diabetics worldwide by enabling patients with type 2 diabetes to begin insulin therapy earlier, without needles. Oramed's oral insulin is in advanced phase 3 clinical trials under the US FDA and the European EMA for the treatment of type 2 diabetes. In addition to oral insulin, the company's proprietary POD technology can potentially be used to orally administer a number of protein-based therapies that are presently available only via injection.
Cumulative Funding Raised Over Time ($)
$50.0MDec 2015
$68.1MJul 2018
$73.1MNov 2014
$123.1MNov 2021
$127.1MOct 2016
Latest News
growth-negative
The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable
Oramed Pharmaceuticals Inc. has experienced a significant decline in its stock price over the past three years, with a 67% drop. The companys revenue has decreased by 44% per year, which is concerning for a pre-profit company. Despite a 2.2% increase in shareholder value this year, it falls short of the market average, indicating potential issues with the companys business model. The article suggests that Oramed Pharmaceuticals is struggling with declining revenue and losses, leading to a negative impact on its stock performance. The company is involved in the healthcare sector, with a focus on AI-driven diagnostics and drug discovery.
growth-positive
Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company...
Oramed Pharmaceuticals Inc. is advancing its oral insulin program independently, launching a new U.S. trial targeting high-responder subgroups. The company has terminated its joint venture with Hefei Tianhui Biotech Co. Ltd. and is focusing on strategic investments in innovative biomedical companies like Scilex Holdings, Alpha Tau Medical, BioXcel Therapeutics, and Pelthos Therapeutics. Orameds diversified investment portfolio has delivered strong returns, and the company plans to reward shareholders with a one-time dividend. Oramed aims to continue its growth through strategic partnerships and innovation, leveraging its extensive network and regulatory expertise.
Product StagePartnersInvestment
growth-positive
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, is advancing its oral insulin program independently after terminating a joint venture with Hefei Tianhui Biotech Co. Ltd. due to unmet financial conditions. The company is launching a new U.S.-based trial involving 60 patients to validate its oral insulin formulation, targeting high-responder subgroups identified in previous trials. Oramed is focused on strategic partnerships, innovation, and value-driven expansion to accelerate growth and reward shareholders, including plans for a one-time dividend. The companys diversified investment portfolio has delivered strong returns, reinforcing its commitment to long-term shareholder value.
Product StagePartners
growth-positive
Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase
Scilex Holding Company, a revenue-generating firm specializing in non-opioid pain management products, announced the repurchase of 3,130,000 warrants from Oramed Pharmaceuticals Inc. for $13 million. This transaction is part of an option agreement allowing Scilex to repurchase up to 6,500,000 warrants for a total of $27 million. The company still holds the option to buy the remaining 3,370,000 warrants for $14 million by December 31, 2025. Scilexs commercial products include FDA-approved treatments like ZTlido®, ELYXYB®, and Gloperba®. The move is seen as growth-positive, enhancing Scilexs financial and strategic positioning.
Investment
growth-positive
Oramed: Q2 Earnings Snapshot
Oramed Pharmaceuticals Inc. reported a net income of $13.3 million for its second quarter, translating to a profit of 31 cents per share. However, when adjusted for non-recurring gains, the company experienced a loss of 5 cents per share. This financial report was generated using data from Zacks Investment Research. The report highlights the companys financial performance, indicating a positive impact on its growth due to the reported net income.
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $149.13M |
| Last funding | $50M |
| Stage | Public |
| Rounds | 10 |
| Investors | 3 |
Team Members
6
Employees: 11-50
Web & Social Links
| Website | oramed.com |
Locations
Mamilla Road 20, Jerusalem
1185 Avenue of the Americas, New York, NY, USA
Photos & Videos
3 item(s)
Oramed Pharmaceuticals Business
Business models
B2B, B2C, B2B2C, B2G
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsMoleculesTags (7)
oral-drugsmedical-technologiespharmaceuticalsbiotechnologydrug-deliverydiabetespharma-companiesGeographic Markets
AsiaUnited StatesEuropeSouth AmericaOramed Pharmaceuticals Financials
$149.13M
Total funding
Undisclosed
Capital raised
$50M
Last funding
Public
Funding stage
10
Total rounds
3
Investors
Cumulative Funding Raised Over Time ($)
$50.0MDec 2015
$68.1MJul 2018
$73.1MNov 2014
$123.1MNov 2021
$127.1MOct 2016
Private Equity Funding
PIPE
Nov 2021
$50M
Undisclosed Investor(s)
PIPE
Jul 2018
$18.1M
Undisclosed Investor(s)
PIPE
Oct 2016
$4M
Hefei Tianhui Incubator of Technologies
PIPE
Dec 2015
$50M
Hefei Tianhui Incubator of Technologies
PIPE
Nov 2014
$5M
Guangxi Wuzhou Pharmaceutical Group
Non-Equity Funding
GrantEvent
Jan 2013
$31.5K
Public Offering / Exit
POEvent
Mar 2020
Undisclosed
POEvent
Jul 2017
Undisclosed
POEvent
Sep 2012
Undisclosed
POEvent
Apr 2006
Undisclosed
Oramed Pharmaceuticals Lifecycle
Cumulative Funding Raised Over Time
$50.0MDec 2015
$68.1MJul 2018
$73.1MNov 2014
$123.1MNov 2021
$127.1MOct 2016
All Events
PIPE
Nov 2021
$50M
Undisclosed Investor(s)
PIPE
Jul 2018
$18.1M
Undisclosed Investor(s)
PIPE
Oct 2016
$4M
Hefei Tianhui Incubator of Technologies
PIPE
Dec 2015
$50M
Hefei Tianhui Incubator of Technologies
PIPE
Nov 2014
$5M
Guangxi Wuzhou Pharmaceutical Group
GrantEvent
Jan 2013
$31.5K
POEvent
Mar 2020
Undisclosed
POEvent
Jul 2017
Undisclosed
POEvent
Sep 2012
Undisclosed
POEvent
Apr 2006
Undisclosed
Oramed Pharmaceuticals News
104 articles
growth-negative
The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable
Oramed Pharmaceuticals Inc. has experienced a significant decline in its stock price over the past three years, with a 67% drop. The companys revenue has decreased by 44% per year, which is concerning for a pre-profit company. Despite a 2.2% increase in shareholder value this year, it falls short of the market average, indicating potential issues with the companys business model. The article suggests that Oramed Pharmaceuticals is struggling with declining revenue and losses, leading to a negative impact on its stock performance. The company is involved in the healthcare sector, with a focus on AI-driven diagnostics and drug discovery.
growth-positive
Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company...
Oramed Pharmaceuticals Inc. is advancing its oral insulin program independently, launching a new U.S. trial targeting high-responder subgroups. The company has terminated its joint venture with Hefei Tianhui Biotech Co. Ltd. and is focusing on strategic investments in innovative biomedical companies like Scilex Holdings, Alpha Tau Medical, BioXcel Therapeutics, and Pelthos Therapeutics. Orameds diversified investment portfolio has delivered strong returns, and the company plans to reward shareholders with a one-time dividend. Oramed aims to continue its growth through strategic partnerships and innovation, leveraging its extensive network and regulatory expertise.
Product StagePartnersInvestment
growth-positive
Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, is advancing its oral insulin program independently after terminating a joint venture with Hefei Tianhui Biotech Co. Ltd. due to unmet financial conditions. The company is launching a new U.S.-based trial involving 60 patients to validate its oral insulin formulation, targeting high-responder subgroups identified in previous trials. Oramed is focused on strategic partnerships, innovation, and value-driven expansion to accelerate growth and reward shareholders, including plans for a one-time dividend. The companys diversified investment portfolio has delivered strong returns, reinforcing its commitment to long-term shareholder value.
Product StagePartners
growth-positive
Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase
Scilex Holding Company, a revenue-generating firm specializing in non-opioid pain management products, announced the repurchase of 3,130,000 warrants from Oramed Pharmaceuticals Inc. for $13 million. This transaction is part of an option agreement allowing Scilex to repurchase up to 6,500,000 warrants for a total of $27 million. The company still holds the option to buy the remaining 3,370,000 warrants for $14 million by December 31, 2025. Scilexs commercial products include FDA-approved treatments like ZTlido®, ELYXYB®, and Gloperba®. The move is seen as growth-positive, enhancing Scilexs financial and strategic positioning.
Investment
growth-positive
Oramed: Q2 Earnings Snapshot
Oramed Pharmaceuticals Inc. reported a net income of $13.3 million for its second quarter, translating to a profit of 31 cents per share. However, when adjusted for non-recurring gains, the company experienced a loss of 5 cents per share. This financial report was generated using data from Zacks Investment Research. The report highlights the companys financial performance, indicating a positive impact on its growth due to the reported net income.
growth-positive
With Substantial Liquidity, ORMP Has Generated Gains & Income From Investment Portfolio
Oramed Pharmaceuticals (NASDAQ:ORMP) is leveraging its substantial liquidity, with $74.5 million in cash as of March 2025, to invest in early-stage companies and advance its strategic initiatives. The company has invested in Scilex Holding Company, providing collateralized financing and entering into a warrant repurchase agreement worth $27 million plus $1.5 million in option payments. Oramed has a joint venture with Hefei Tianhui Biotech (HTIT) called OraTech Pharmaceuticals, focusing on oral insulin delivery. OraTech plans a spin-off and IPO on Nasdaq, with HTIT and ORMP planning additional investments of $20 million and $7.5 million, respectively. Oramed aims to distribute its 50% stake in OraTech to shareholders. The company is largely pre-revenue but recognized $2 million in revenue from a license agreement with HTIT.
InvestmentPartnersPublic Trading
growth-negative
We're Not Very Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Rate
Oramed Pharmaceuticals, a company listed on NASDAQ, is currently facing concerns regarding its cash burn rate. Despite having a cash reserve of $131 million as of March 2025 and no debt, the company has reported a significant increase in its cash burn by 67% over the past year, amounting to $10 million. This situation suggests that while the company has a long cash runway, its increased cash burn could lead to future funding needs. The company reported minimal revenue of $2 million in the last twelve months, indicating that it is still in the R&D stage and not yet generating significant operating revenue. Shareholders may need to consider the possibility of the company raising additional funds through issuing new shares or taking on debt.
growth-negative
The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable
Oramed Pharmaceuticals Inc. has experienced a significant decline in its stock performance over the past three years, with a 53% drop in share price. The decline has accelerated recently, with a 10% decrease in the last three months. The companys revenue has decreased by 54% annually over the past three years, contributing to the negative stock performance. Despite the broader market gaining about 13%, Orameds shareholders faced a 6.5% loss over the past year. The company is not currently profitable, and its financial health is under scrutiny, with two warning signs highlighted in investment analysis.
growth-negative
Oramed: Q1 Earnings Snapshot
Oramed Pharmaceuticals Inc. reported a financial loss of $7.6 million for the first quarter, translating to a loss of 19 cents per share. The company, based in New York, generated $2 million in revenue during this period. The report suggests a challenging financial performance for the quarter, which could impact the companys growth negatively. The data for this report was sourced from Zacks Investment Research and processed by Automated Insights.
growth-negative
WEX, Acelyrin, and More Stocks See Action From Activist Investors
The article discusses the involvement of activist investors with companies such as WEX and Acelyrin. These companies have seen action from these investors, as indicated by 13D filings with the Securities and Exchange Commission. A 13D filing is required when an entity acquires more than 5% of a companys securities, suggesting significant investor interest or potential influence over company decisions. The article highlights the potential impact of such investor actions on the companies involved, which could be growth-negative due to the pressure and changes activist investors might push for.
growth-positive
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
Alpha Tau Medical Ltd. has successfully closed a registered direct offering, raising approximately $36.9 million from an affiliate of Oramed Pharmaceuticals Inc. This investment will support Alpha Taus growth, including expansion into multiple internal organ applications, scaling up manufacturing capabilities, and commercial preparations. The partnership with Oramed will also provide strategic services such as investor and public relations. Alpha Tau is currently conducting four active U.S. trials and is expanding its clinical and commercial roadmap. The offering was made under a registration statement filed with the SEC.
PIPE/POPartnersProduct Stage
growth-positive
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed Pharmaceuticals Inc. has made a strategic investment in Alpha Tau Medical Ltd., acquiring approximately 14.1 million shares at $2.612 per share through a registered direct offering. This partnership aims to leverage Orameds expertise in capital markets to support Alpha Taus innovative cancer therapy technology, Alpha DaRT®. The collaboration includes a three-year service agreement where Oramed will provide strategic guidance and appoint two directors to Alpha Taus Board. This alliance is expected to accelerate Alpha Taus clinical trials, manufacturing scale-up, and commercialization efforts, aligning with Orameds growth strategy in therapeutic delivery technologies.
PartnersInvestment
growth-positive
/PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral...
Oramed Pharmaceuticals Inc. has made a strategic investment in Alpha Tau Medical Ltd., acquiring approximately 14.1 million shares at $2.612 per share through a registered direct offering. This partnership aims to leverage Orameds expertise in capital markets to support Alpha Taus innovative cancer therapy technology, Alpha DaRT®. The collaboration includes a three-year service agreement where Oramed will provide strategic guidance and appoint two directors to Alpha Taus board. This alliance is expected to accelerate Alpha Taus clinical trials and commercialization efforts, particularly in the U.S., while expanding manufacturing capabilities. Both companies share a vision of revolutionizing therapeutic delivery, with Oramed focusing on oral drug delivery and Alpha Tau on precision radiation therapy.
PartnersInvestment
growth-positive
ORMP: Upcoming Expected Milestones Include OraTech Spin-Off & IPO, Launch of Phase 3 Trial
Oramed Pharmaceuticals (NASDAQ:ORMP) is planning a spin-off and IPO of its joint venture, OraTech Pharmaceuticals, formed with Hefei Tianhui Biotech (HTIT). The JV partners have amended their agreement to facilitate this, with HTIT and Oramed planning investments of $40 million and $7.5 million, respectively. OraTech will focus on developing and commercializing innovative products globally, leveraging HTITs manufacturing technologies and Orameds oral insulin and POD™ pipeline. A Phase 3 clinical trial for oral insulin in the U.S. is planned, targeting specific patient subpopulations. The IPO will see Oramed distribute a majority of its 50% stake in OraTech to its shareholders.
Public TradingInvestmentPartnersProduct Stage
growth-positive
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential
Oramed Pharmaceuticals Inc., with a market cap of $105.62 million, is focused on developing innovative oral drug delivery technologies, particularly for diabetes treatment. The company recently announced a strategic alliance with Hefei Tianhui Biotech Co. to spin off its Protein Oral Delivery technology into OraTech Pharmaceuticals. This collaboration aims to accelerate the development of its oral insulin product. Oramed is currently pre-revenue but has become profitable in the last year, although earnings are expected to decline over the next three years. The company is debt-free and has a seasoned management team, positioning it well for future advancements.
Partners
growth-positive
Oramed Pharmaceuticals Issues Letter to Shareholders
Oramed Pharmaceuticals Inc. has announced a joint venture with Hefei Tianhui Biotech Co., Ltd to form OraTech Pharmaceuticals Inc., focusing on the development of oral insulin. The partnership aims to leverage Orameds oral drug delivery technology and HTITs manufacturing capabilities. OraTech plans to initiate a Phase 3 clinical trial in the U.S. and has submitted a Marketing Authorization Application in China. Oramed will distribute a majority of its holding in OraTech to its shareholders via a dividend, coinciding with OraTechs public listing. The company expects to receive royalties from sales in China and from Scilex products.
Product StagePartners
growth-negative
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch
The article discusses the U.S. stock markets mixed performance amid economic complexities, highlighting penny stocks as potential growth opportunities. Oramed Pharmaceuticals Inc., a company focused on diabetes treatment and polypeptide delivery, is featured with a market cap of $87.48 million. Despite being debt-free and having experienced management, Oramed is pre-revenue and recently profitable, with a challenging earnings growth rate. The company anticipates a substantial revenue growth of 256.94% annually, but future earnings are forecasted to decline significantly over the next three years. This suggests a growth-negative outlook for Oramed Pharmaceuticals.
Product Stage
growth-positive
New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed...
OraTech Pharmaceuticals Inc., a new standalone company, is set to focus on oral drug delivery, particularly oral insulin, with strategic investments from HTIT and Oramed Pharmaceuticals. The company will leverage Orameds POD™ technology and HTITs manufacturing capabilities. OraTech plans to go public on Nasdaq, with Oramed shareholders receiving direct stakes. A combined investment of $75 million will support development and commercialization efforts, including a Phase 3 clinical trial in the U.S. OraTech aims to redefine diabetes care and expand oral biologics potential. HTIT will also provide a supply agreement for oral insulin capsules.
Product StageInvestmentAcquisitionPublic TradingPartners
growth-positive
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
Oramed Pharmaceuticals Inc. has announced the spin-off of its Protein Oral Delivery (POD™) technology into a new company, OraTech Pharmaceuticals Inc., in partnership with Hefei Tianhui Biotech Co., Ltd. (HTIT). OraTech will focus on oral drug delivery, particularly oral insulin, and will receive a $75 million investment from Oramed and HTIT. The company plans to go public on Nasdaq and will have global marketing rights to Orameds POD™ technology. A new Phase 3 trial for oral insulin is expected to begin in the U.S. this quarter. OraTech will also receive royalties from sales in China, where commercialization preparations are underway.
InvestmentPartnersPublic TradingProduct Stage
growth-negative
3 US Penny Stocks With Market Caps Above $40M
The article discusses the current state of U.S. stock indices, which are reaching new highs due to strong tech earnings and positive signals from the Federal Reserve. Amidst this market optimism, investors are exploring opportunities in penny stocks, which are often overlooked but have potential for growth. Heritage Global Inc., a company with a market cap of $64.69 million, is highlighted as a noteworthy penny stock. Despite a decline in revenue and net income compared to the previous year, the company benefits from strong cash flow coverage over its debt and has recently completed share buybacks. The article suggests that Heritage Global is trading below its estimated fair value, making it a potential investment opportunity.
growth-positive
ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements
Oramed Pharmaceuticals (NASDAQ:ORMP) is advancing its clinical R&D efforts by focusing on a Phase 3 trial for ORMD 0801, targeting specific patient subpopulations that showed positive responses in previous trials. The company has entered into a joint venture with Hefei Tianhui Biotech Co., Ltd. to develop and commercialize innovative products globally. Additionally, Oramed has strengthened its cash position with $142 million in cash and equivalents, supported by agreements with Scilex Holding Company. The company also repurchased shares worth $1.3 million in 3Q24, indicating a robust financial strategy. These developments suggest a positive growth trajectory for Oramed.
PartnersInvestment
growth-positive
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M
Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing antibody-based therapeutics for oncology treatment. Despite being unprofitable and experiencing increased net losses, the company maintains strong short-term assets exceeding its liabilities, with no long-term liabilities, providing financial flexibility. Recent developments include receiving FDA Fast Track Designation for CTX-009 and promising early-stage trial results for CTX-471 in specific cancer types. However, challenges such as shareholder dilution by 8% last year and high share price volatility remain concerns for investors. The company is part of the broader U.S. penny stock market, which is gaining attention for its potential growth opportunities amid a technology-led stock market rally.
growth-positive
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, has announced a restructuring of its existing Senior Secured Promissory Note with Scilex Holding Company. Oramed has entered into agreements with affiliates of Murchinson and 3i LP for a new $50 million financing through the issuance of senior secured convertible notes and warrants. The restructuring involves converting $22.5 million of Scilexs outstanding principal into a new note and warrants, with a portion of the proceeds used to repay the original note. Additionally, Oramed and other investors will acquire an 8% royalty on certain Scilex products, with Oramed receiving 50% of the proceeds. The transactions are expected to close by October 7, 2024.
Investment
growth-positive
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
Oramed Pharmaceuticals Inc. announced a restructuring of its Senior Secured Promissory Note with Scilex Holding Company. The restructuring involves new tranche B senior secured convertible notes worth $50 million and warrants for 7.5 million shares. Oramed will restructure $22.5 million of the outstanding principal balance, receiving a $25 million note and warrants for 3.75 million shares of Scilex. Additionally, Oramed and other investors will acquire an 8% royalty on Scilexs product sales, including ZTlido. The restructuring aims to enhance the value of Orameds investment in Scilex, aligning with its strategy to maximize shareholder value. The closing of the new financing and royalty transaction is expected by October 7, 2024.
Investment
growth-positive
Scilex Holding Starts $50 Million Registered Direct Offering of Convertible Notes
Scilex Holding has initiated a $50 million registered direct offering of convertible notes. This move is aimed at raising capital, which is generally seen as a positive step for the companys growth and financial health. The offering is part of Scilexs strategy to secure additional funding, which could be used for various corporate purposes, including expansion or debt repayment. The article does not mention specific investors involved in this offering. The event highlights Scilexs efforts to strengthen its financial position through strategic financing activities.
Investment
growth-positive
/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral...
Oramed Pharmaceuticals Inc. announced a restructuring agreement involving its Senior Secured Promissory Note with Scilex Holding Company. The restructuring includes new tranche B senior secured convertible notes worth $50 million and warrants for 7.5 million shares. Oramed will restructure $22.5 million of Scilexs existing note, receiving a $25 million note and warrants for 3.75 million shares. Additionally, Oramed and other investors will acquire an 8% royalty on Scilexs product sales, including ZTlido, with Oramed entitled to 50% of the proceeds. This restructuring aims to enhance Orameds investment value in Scilex, aligning with its strategy to maximize shareholder value. The closing of the new financing is expected around October 7, 2024.
Investment
growth-positive
ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks
Oramed Pharmaceuticals (NASDAQ: ORMP) has reappointed Avraham Gabay as CFO, Secretary, and Treasurer, replacing David Silberman who resigned for personal reasons. Gabays extensive experience includes roles at Oravax Inc., BiomX Inc., and Orcam Technologies Ltd. Orameds strong cash position, bolstered by repayments from Scilex Holding Company, supports its development activities and a new $20 million stock buyback program. The company plans to launch a new Phase 3 trial for its oral insulin candidate, ORMD 0801, targeting specific patient subgroups identified in previous trials. Orameds financial flexibility and strategic initiatives are expected to drive growth.
Management ChangesInvestment
growth-positive
Oramed: Q2 Earnings Snapshot
Oramed Pharmaceuticals Inc. reported earnings of $9.2 million in its second quarter. The New York-based company said it had a profit of 22 cents per share. The story was generated by Automated Insights using data from Zacks Investment Research.
Investment
growth-positive
3 Micro-Cap Moonshots for Fearless Investors
The article discusses the potential of investing in micro-cap stocks, despite their inherent risks. It highlights three companies: Amplify Energy, an independent developer focused on acquiring and exploiting oil and natural gas properties; Spero Therapeutics, a company developing medicines for multidrug-resistant infections; and Oramed Pharmaceuticals, a biotech company aiming to simplify drug delivery through oral capsules. The article suggests that these companies, despite being relatively young and unproven, could offer significant growth potential for investors willing to take on the associated risks.
Investment
growth-positive
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
Oramed Pharmaceuticals Inc. has announced that its Board of Directors has authorized a common stock repurchase plan. The plan allows for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934. The manner, timing and number of shares purchased will be at the Companys discretion. The Stock Buy Back Program does not obligate the Company to purchase any shares and expires in 12 months.
Investment
growth-positive
Oramed Letter to Shareholders
Oramed Pharmaceuticals Inc. has announced a $20 million stock repurchase program, demonstrating confidence in the companys value and potential. The company has received $40 million out of the total $102 million principal from Scilex Holding Company for its Senior Secured Note. Oramed is also in dialogue with the U.S. Food and Drug Administration regarding a new Phase 3 protocol for oral insulin therapy. Furthermore, Oramed and its long-term partner, Hefei Tianhui Biotech Co., Ltd. (HTIT), are finalizing a joint venture centered around Orameds oral drug delivery technology, with HTIT committing $70 million in cash and Oramed investing $25 million in cash and stock.
InvestmentPartners
Growth-Positive
ORMP: Moving Oral Delivery Platform Forward, + Potential to Generate Royalties
Oramed Pharmaceuticals CFO, David Silberman, has announced his intention to resign effective July 12, 2024. The company has started looking for a new CFO and believes it has the financial flexibility to continue its development activities. Oramed has also entered into a joint venture with Hefei Tianhui Biotech to develop and commercialize products based on Orameds oral insulin and Protein Oral Delivery pipeline. The company has also acquired the rights to PeriTech’s technology for the delivery of topical/dermatology agents and entered into a licensing agreement with Genomma Lab Internacional.
Management ChangesPartnersInvestment
Growth-Positive
Oramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)
Oramed Pharmaceuticals has reported its first quarter 2024 results, showing a net income of US$1.54m, a significant improvement from a US$3.40m loss in 1Q 2023. The companys earnings per share (EPS) also increased to US$0.038, up from a loss of US$0.085 in the same period the previous year. The companys shares have risen by 1.9% over the past week. However, the article also mentions three warning signs spotted with Oramed Pharmaceuticals, including one potentially serious issue.
None
Growth-Positive
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Scilex Holding Company, a company focused on non-opioid pain management products, has announced that it has paid off the remaining balance of approximately $1.3 million under the convertible debentures previously issued and sold to YA II PN, Ltd. (Yorkville) in March 2023. Additionally, Scilex has voluntarily made an early payment of $15 million under the senior secured promissory note issued to Oramed Pharmaceuticals Inc. in September 2023. The companys CEO, Jaisim Shah, stated that this is a pivotal moment for Scilex, signaling their readiness to embrace new opportunities and transform the lives of patients with acute and chronic pain.
Investment
growth-positive
Oramed Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
Oramed Pharmaceuticals has reported its full year 2023 results, showing a net income of US$5.53m, up from a loss of US$36.6m in FY 2022. The companys EPS also increased to US$0.14, up from a loss of US$0.94 in FY 2022. Revenue and earnings both exceeded analyst estimates. However, the companys shares are down 13% from a week ago. The report also warns of three warning signs in the companys investment analysis.
Investment
growth-positive
Oramed Letter to Shareholders
Oramed Pharmaceuticals Inc. has announced a joint venture with Chinese partner HTIT, following the successful completion of Phase 3 trials of oral insulin for type 2 diabetes in China. The joint venture will focus on the development, marketing, and global commercialization of products derived from Orameds oral insulin and Protein Oral Delivery (POD) pipeline. HTIT will invest $70 million into the venture, with Oramed contributing $20 million. Oramed also announced the acquisition of rights to PeriTech Pharma Ltd.s film-forming technology for the delivery of topical/dermatology agents.
InvestmentPartnersAcquisition
growth-positive
ORMP: Multiple Potential Applications for Proprietary Oral Protein Delivery Platform
Oramed Pharmaceuticals has entered into a joint venture with Hefei Tianhui Biotech to develop and commercialize products based on Orameds oral insulin and Protein Oral Delivery (POD) pipeline. The partners will invest $70 million and $20 million respectively, with Orameds contribution consisting of $10 million in cash and $10 million in ORMP shares. The joint venture will also launch a Phase 3 oral insulin trial in the U.S. Additionally, Oramed is exploring opportunities to advance its assets for nonalcoholic steatohepatitis (NASH), obesity, and a COVID-19 vaccine.
PartnersInvestmentExpand
growth-negative
Oramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year ago
Oramed Pharmaceuticals Inc. has experienced a challenging year, with its stock price dropping by 63%, despite a market gain of 13%. The company is not currently profitable and its revenue fell by 0.3% last year, which is concerning for investors. Insiders have been buying shares, indicating some confidence in future growth, but the lack of revenue growth and profitability raises caution. The article suggests that while market conditions can impact share prices, investors should focus on the quality of the business before investing. The analysis is based on historical data and analyst forecasts, and does not constitute financial advice.
growth-negative
Oramed Pharmaceuticals (NASDAQ:ORMP) investors are sitting on a loss of 63% if they invested a year ago
Oramed Pharmaceuticals Inc. has seen a significant drop in its share price over the past year, with a decrease of 63%. Over a three-year period, the stock has fallen by 11%. The companys revenue also fell by 0.3% in the last year. Despite this, insiders have been buying shares in the company over the past twelve months. The companys future earnings will be a key factor in determining whether current shareholders make money.
CustomersInvestment
growth-positive
ORMP: Distribution Deals, JVs in Anticipation of Commercializing ORMD-0801
Oramed Pharmaceuticals is advancing its oral protein delivery platform, focusing on treatments for diabetes, NASH, obesity, and potentially a COVID vaccine. The company has entered into a joint venture with Hefei Tianhui Biotechnology Co. (HTIT) to develop and commercialize products based on Orameds oral insulin and POD™ pipeline. Each partner will initially own a 50% share in the JV, with HTIT investing $60 million and Oramed $10 million. Additionally, Oramed has signed an exclusive distribution agreement with Medicox for ORMD-0801 in South Korea. The company sees significant opportunities for oral insulin treatments, especially in markets like China and South Korea, where diabetes prevalence is high.
PartnersInvestment
Growth-Positive
ORMP: Distribution Deals, JVs in Anticipation of Commercializing ORMD-0801
Oramed Pharmaceuticals has signed a non-binding term sheet with Hefei Tianhui Biotechnology Co. (HTIT) to establish a joint venture (JV) focusing on the development and commercialization of innovative products based on Oramed’s oral insulin and Protein Oral Delivery (POD) pipeline. The JV will leverage HTIT’s manufacturing capabilities and technologies. Each partner will initially own a 50% share in the JV and have equal representation on the board. HTIT and Oramed are expected to make initial investments of $60 million and $10 million, respectively. Orameds lead asset ORMD-0801 is being evaluated as an oral insulin treatment for Type 1 and Type 2 diabetes, as well as for NASH.
PartnersInvestment
Growth-Negative
Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company
Sorrento Therapeutics, a biopharmaceutical company, has announced the completion of the sale of certain securities it held in Scilex Holding Company. The sale, which was finalized on September 21, 2023, saw Scilex acquire all shares of its common and preferred stock owned by Sorrento, as well as all warrants for the purchase of Scilex common stock owned by Sorrento. The total consideration for the sale was $110 million, which included cash payments and the assumption of a $100 million senior secured term loan facility provided by Oramed Pharmaceuticals to Sorrento. As a result, Sorrento no longer has a controlling interest in Scilex.
Acquired-byPartners
Growth-Positive
Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
Scilex Holding Company, a company focused on non-opioid pain management products, has completed the acquisition of securities from Sorrento Therapeutics. As part of the deal, Scilex has assumed approximately $100 million in Sorrentos debt. The total consideration for the acquisition includes $110 million in cash and debt assumption, $12.25 million for legal fees and expenses, and a credit bid for all amounts owed to Scilex by Sorrento. Concurrently, Scilex entered into a Securities Purchase Agreement with Oramed Pharmaceuticals, assuming Sorrentos debt to Oramed. The company is committed to delivering long-term value to shareholders and advancing non-opioid therapies for acute and chronic pain patients.
AcquisitionInvestment
growth-positive
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
Oramed Pharmaceuticals Inc. has entered into a Securities Purchase Agreement with Scilex Holding Company, replacing a previous agreement with Sorrento Therapeutics. As part of the agreement, Scilex issued a Senior Secured Promissory Note to Oramed, assuming Sorrentos $100 million senior secured Debtor In Possession term loan facility with Oramed. Scilex also issued new warrants to Oramed to purchase up to 13 million shares of Scilex common stock. The transactions were approved by the U.S. Bankruptcy Court.
InvestmentAcquisition
growth-positive
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
Scilex Holding Company, a subsidiary of Sorrento Therapeutics, has announced that it will acquire all shares of Scilex common stock owned by Sorrento, as well as all shares of Scilex preferred stock and all warrants for the purchase of shares of Scilex common stock owned by Sorrento. The total consideration for the acquisition is $110 million, which includes cash payments of $10 million and the assumption of certain indebtedness of Sorrento in the amount of $100 million. The company will also assume certain legal fees and expenses amounting to approximately $12.25 million. The transactions are expected to close on or about September 19, 2023.
AcquisitionInvestment
growth-positive
Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally
Oramed Pharmaceuticals Inc. has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. (HTIT) to establish a joint venture (JV) based on Orameds oral drug delivery technology. The proposed JV will focus on the development and worldwide commercialization of products based on Orameds oral insulin and POD™ (Protein Oral Delivery) pipeline and HTITs manufacturing capabilities and technologies. HTIT will invest $60 million and Oramed will invest $10 million into the JV. The JV will be responsible for developing, marketing, and commercializing drug products globally.
PartnersInvestment
growth-positive
Oramed to Present at the 83rd American Diabetes Association Conference
Oramed Pharmaceuticals has been selected to present an oral abstract presentation at the American Diabetes Associations 83rd Scientific Sessions. The presentation will discuss the results of Orameds Phase 2 oral insulin trial for the treatment of NASH and Type 2 Diabetes, highlighting the potential reduction of liver fibrosis and fat in patients. The presentation will take place on June 23, 2023, in San Diego, California. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
Customers
Neutral
Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans
Oramed Pharmaceuticals has been examined for its cash burn rate, with the company having a cash runway of 6.2 years as of March 2023. The company managed to reduce its cash burn by 36% over the last year, however, its operating revenue remained flat. The companys market capitalisation stands at $154m and it burnt through $25m last year, which is 16% of the companys market value. The analysis suggests that while the companys cash burn situation warrants attention, it is not a cause for concern.
Investment
Growth-Positive
ORMP: Advancing Development Efforts in China
Oramed Pharmaceuticals partner in China, Hefei Tianhui Biotechnology Co., has completed a Phase 3 oral insulin clinical trial in China and submitted a marketing authorization application to China’s regulatory body. The completion of the Phase 3 trials of oral insulin in type 2 diabetes (T2D) in China and application submission furthers the partners’ ability to commercialize ORMD-0801 in China. Orameds licensing agreement with HTIT included milestone payments to ORMP and potential royalty revenue when / if ORMD-0801 is commercialized in China.
PartnersExpand
growth-positive
Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit
Oramed Pharmaceuticals announced that its Chief Scientific Officer will deliver a presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit. The presentation will discuss Orameds oral delivery technology and insights from the companys recent Phase 3 oral insulin clinical trials. The event will take place on May 31, 2023, in Boston, MA.
Customers
growth-positive
Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China
Oramed Pharmaceuticals has announced that its strategic partner, Hefei Tianhui Biotechnology Co. Ltd. (HTIT), has completed Phase 3 trials of oral insulin in China for the treatment of type 2 diabetes. The trials showed a significant reduction in A1C levels in patient subgroups. HTIT has submitted the data to the National Medical Products Administration for regulatory approval. Oramed is exploring ways to move forward with its oral insulin product based on the positive findings. The analysis of Orameds Phase 3 trial in the US also found that specific patient subpopulations responded well to oral insulin, with a statistically significant reduction in HbA1c. Oramed and HTIT are excited about the potential commercialization of oral insulin in China.
Partners
growth-positive
Oramed Appoints Ben Shapiro to its Board of Directors
Oramed Pharmaceuticals Inc. has announced the appointment of Benjamin Shapiro to its Board of Directors, effective May 1, 2023. Shapiro, a successful entrepreneur and business professional, is a co-founder of The Daily Wire and host of The Ben Shapiro Show. He owns over four percent of Orameds outstanding stock, making him a significant shareholder in the company. Orameds CEO, Nadav Kidron, expressed excitement about Shapiros appointment, stating that his unique talents and qualifications are expected to bring real value to the board and help build shareholder value.
Management Changes
The past year for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable
growth-negative
Oramed Pharmaceuticals Issues Shareholder Update
Oramed Pharmaceuticals is conducting a comprehensive analysis of data from its discontinued Phase 3 oral insulin trials. The companys management and Board of Directors are also reviewing strategic alternatives to enhance shareholder value, which may include an acquisition, merger, business combination, or other transaction. Oramed has not set a timetable for completion of this review process. The companys CEO stated that the clinical team will continue to analyze the Phase 3 data and evaluate the optimal way to move forward with their oral insulin assets and platform technology. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
Management Changes
ORMP: ORA-D-013-1 Failed To Meet Endpoints; Ending T2D Oral Insulin Efforts
Growth-Negative
Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study
Oramed Pharmaceuticals Inc announced that its Phase 3 trial (ORA-D-013-1) for ORMD-0801, a treatment for Type 2 Diabetes (T2D), did not meet its primary or secondary endpoints. The trial enrolled 710 T2D patients with inadequate glycemic control. The primary endpoint was improving glycemic control as assessed by the mean change from baseline in A1C at 26 weeks, and the secondary endpoint was the mean change from baseline in fasting plasma glucose at 26 weeks. As a result, Oramed plans to discontinue its oral insulin clinical activities for T2D.
Customers
growth-negative
Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes
Oramed Pharmaceuticals Inc. has announced that its Phase 3 clinical trial for ORMD-0801, a drug for Type 2 Diabetes, did not meet its primary or secondary endpoints. As a result, the company expects to discontinue its oral insulin clinical activities for Type 2 Diabetes. CEO Nadav Kidron expressed disappointment at the outcome, given positive results from prior trials. The company plans to share relevant learnings and future plans once full data from the studies are available.
Management Changes
growth-negative
Why Oramed Pharmaceuticals Stock Is Crashing Today
Oramed Pharmaceuticals stock is crashing due to a major flop in treating type 2 diabetes with their lead pipeline candidate. The candidate is still being evaluated as a potential treatment for NASH. This news has had a negative impact on the companys growth.
Customers
Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation
growth-positive
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
Oramed Pharmaceuticals has been granted a patent for methods and compositions for treating diabetes through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1). The patent serves as an extension to a previous patent granted in May 2022. Oramed is a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms. The company is currently evaluating its lead candidate, ORMD-0801, in two pivotal Phase 3 trials, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes.
Customers
growth-positive
Oramed Letter to Shareholders
Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, expects to announce topline results for its Phase 3 oral insulin trials in mid-January 2023. The company also achieved positive results in its Phase 2 NASH trial and signed a definitive deal with Medicox to commercialize oral insulin in South Korea. Oramed finished the third quarter with $160 million in cash and investments. Additionally, the companys subsidiary, Oravax, reported positive preliminary data from its Phase 1 clinical trial for an oral COVID-19 vaccine. Oramed is also developing an oral GLP-1 analog capsule. The company is optimistic about the upcoming year and is focused on advancing its clinical efforts.
Investment
Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022
growth-positive
Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism
Oramed Pharmaceuticals has announced the publication of an article presenting the results of a 12-week clinical trial for its lead drug candidate ORMD-0801 in patients with Type 2 Diabetes. The trial showed statistically significant reductions in HbA1c levels and the treatment doses were safe and well tolerated. Based on the results, a bedtime dose of 8 mg is being carried forward into Phase 3 registration studies. Oramed is a platform technology pioneer in oral delivery solutions for drugs and is focused on transforming the treatment of diabetes. The company is also developing an oral GLP-1 analog capsule.
Customers
growth-positive
Oramed inks deal to commercialize oral insulin in South Korea
Oramed has granted Medicox an exclusive license to apply for regulatory approval and distribute its oral insulin candidate in Korea. The deal allows Oramed to enter the Korean market while focusing on other key markets. Medicox will purchase the oral insulin candidate at an agreed-upon transfer price and pay up to $18m in developmental milestones and royalties. Orameds oral insulin pill has the potential to be the first commercial oral insulin capsule for diabetes treatment. The drug is currently in Phase 3 studies, with top-line results expected in January next year. Oramed also released positive data from its Phase 2 trial for reducing liver fat content in Type 2 diabetes patients with NASH.
Partners
ORMP: Data from NASH Phase 2 Study – Positive Takeaways
growth-positive
Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH
Oramed Pharmaceuticals has announced additional positive data from its Phase 2 clinical trial for its oral insulin candidate to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis (NASH). The trial demonstrated a positive safety profile and signs of efficacy, with consistent trends across key secondary endpoints. The company believes that its oral insulin may be an ideal treatment option for diabetes and NASH patients, as the global market for drugs to treat NASH is expected to reach $84 billion by 2029. The Phase 2 trial enrolled 32 patients and met its primary endpoint of safety and tolerability. Oramed is a platform technology pioneer in oral drug delivery solutions and is focused on transforming the treatment of diabetes.
CustomersInvestment
Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study
Oramed Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
growth-positive
Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea
Oramed Pharmaceuticals has signed an exclusive commercial distribution agreement with Medicox Co., Ltd. for the distribution of Orameds oral insulin candidate in South Korea. Medicox will have an exclusive license to apply for regulatory approval and distribute the oral insulin candidate for ten years. Oramed will receive up to $18 million in developmental milestones and up to 15% royalties on gross sales. The agreement allows Oramed to focus on other key markets while leveraging Medicoxs commercialization strength. The large market potential in South Korea, where 1 in 7 Koreans over the age of 30 has diabetes, presents a growth-positive opportunity for Oramed.
Partners
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes - Oramed Pharmaceuticals
growth-positive
Oramed hits oral insulin clinical trial milestone
Oramed has completed recruitment for the clinical trial of its oral insulin capsule, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. The study enrolled a total of 710 patients, surpassing the initial target of 675 patients. The primary endpoint of the study is to compare the efficacy of ORMD-0801 to placebo in improving glycemic control. Topline results are expected to be announced in January 2023. Oramed aims to transform the treatment of diabetes through its proprietary lead candidate.
CustomersExpand
growth-positive
Oramed Granted NASH Patent in Europe - Oramed Pharmaceuticals
Oramed Pharmaceuticals has been granted a patent by the European Patent Office for its methods and compositions for treating NAFLD, Hepatic Steatosis, and Sequelae Thereof. The patent was previously granted in the U.S. and is pending in other major markets. Oramed recently announced 100% enrollment in its Phase 2 trial for its oral insulin ORMD-0801 in type 2 diabetes patients with NASH. The global market for drugs to treat NASH is expected to reach $84 billion by 2029. Oramed is a platform technology pioneer in oral drug delivery solutions and is focused on transforming the treatment of diabetes with its proprietary lead candidate, ORMD-0801.
Customers
growth-positive
Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins - Oramed Pharmaceuticals
Oramed Pharmaceuticals has been granted a patent by the European Patent Office for its oral protein delivery platform technology. The patent covers a unique method for the purification of raw protease-inhibiting materials, which are a key component of the platform technology. This patent strengthens Orameds leading position in intellectual property assets related to the oral delivery of therapeutic proteins. Oramed is currently developing its lead drug candidate ORMD-0801, which is in pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule on the market.
Investment
growth-positive
Israeli Oral COVID-19 Vaccine Set To Begin Clinical Trials In South Africa
Oramed Pharmaceuticals has received approval to begin clinical trials for its oral COVID-19 vaccine in South Africa. The company has also received approval to conduct trials in Israel. The vaccine targets three SARS CoV-2 virus structural proteins, potentially making it more effective against current and future variants. The oral vaccine can be taken as a pill, reducing waste and potential side effects. Oramed aims to show proof of concept in humans through the trials and eventually obtain emergency use approval from the US FDA. The company plans to apply for Phase II trials in the US and other countries. The oral vaccine could offer a solution to the COVID-19 pandemic by eliminating barriers to distribution and enabling self-administration at home.
CustomersInvestment
growth-positive
Israeli COVID vaccine in pill form to start clinical trial in Tel Aviv
Oramed Pharmaceuticals, an Israeli company, has developed a single-dose oral version of a prospective COVID-19 vaccine. The company believes that this oral vaccine could be a game-changer in countries with limited infrastructure for vaccine distribution. The pill does not require low-temperature storage and can be self-administered, simplifying logistics. Oramed has received approval to start clinical trials on unvaccinated volunteers, and the trial is expected to begin next month. The CEO of Oramed believes that the oral vaccine, which targets three proteins of the SARS-CoV-2 virus, will be effective against new variants. The company aims to provide a solution for countries struggling to vaccinate their populations and meet the potential demand for booster shots.
Customers
growth-positive
Oramed Initiates Second Phase 3 Oral Insulin Study Under the FDA's Approved Dual Concurrent Protocol
Oramed Pharmaceuticals has announced that it has screened the first patients in its Phase 3 study for its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes. The study is being conducted under FDA approved protocols and will evaluate the efficacy and safety of ORMD-0801 in 1,125 patients. Oramed is the only company conducting two Phase 3 oral insulin studies under an FDA protocol. The company aims to assess the oral insulin capsule in patients who are on diet control alone or on diet and metformin monotherapy. The study is expected to yield compelling results for potential approval.
CustomersInvestment
growth-positive
https://www.jpost.com/health-science/israeli-company-says-oral-covid-19-vaccine-on-its-way-662712
Oramed Pharmaceuticals Inc. is preparing to launch a Phase I clinical trial for an oral COVID-19 vaccine. The company has formed a joint venture with India-based Premas Biotech to develop the vaccine under the company name Oravax Medical Inc. The vaccine is based on Orameds oral delivery technology and Premass vaccine technology. An oral vaccine would eliminate barriers to rapid distribution and could be self-administered at home. The vaccine candidate targets three structural proteins of the novel coronavirus and is expected to be more resistant to COVID-19 variants. It is a yeast-based vaccine, making production time and cost cheaper. Oramed anticipates commencing a clinical study in multiple countries and expects Phase I human trial data to be available within three months.
PartnersInvestment
growth-positive
Oramed Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol
Oramed Pharmaceuticals Inc. has announced that it has enrolled and randomized 25% of the 675 patients planned for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes. The study is one of two concurrent Phase 3 studies conducted under U.S. Food and Drug Administration (FDA) approved protocols. The company is on track to complete randomization of all 675 patients by the end of 2021, with topline results expected next year.
Customers
growth-positive
Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
Oramed Pharmaceuticals Inc. has announced the commencement of patient randomization in its first Phase 3 study of oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes. The study is being conducted in accordance with U.S. Food and Drug Administration (FDA) approved protocols. The study aims to recruit 675 patients who are currently on two or three oral glucose-lowering agents through 75 clinical sites throughout the U.S. The primary endpoint of the study is to compare the efficacy of ORMD-0801 to placebo in improving glycemic control.
Customers
growth-positive
Oramed Reports Positive First in Human Data from Oral Leptin Study
Oramed Pharmaceuticals announced positive results from a proof-of-concept study for its oral leptin drug candidate. The study evaluated the drugs safety and pharmacodynamics in type 1 diabetic patients. The results showed a decrease in glucose levels in patients who received leptin compared to the placebo group. Oramed plans to move forward with a larger study and sees the oral leptin capsule as a potential treatment for weight loss and addressing increasing diabetes rates. Leptin is a protein that regulates hunger and the overall obesity market is expected to reach $15.6 billion in 2024. Oramed Pharmaceuticals is a platform technology pioneer in oral drug delivery solutions for drugs currently delivered via injection.
CustomersExpand
growth-positive
Oramed Initiates Phase 2 NASH Trial of Oral Insulin
Oramed Pharmaceuticals has announced the screening of the first patients in a global trial of its oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH). The trial will be conducted at clinical sites in the EU, US, and Israel and will measure efficacy endpoints via MRI-PDFF for 12 weeks. The previous study showed a 30% relative reduction in liver fat, and Oramed is excited to start this international NASH trial. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
Customers
growth-positive
Oral insulin, by Israeli mom-son team, starts final trials to become world's 1st
Oramed Pharmaceuticals, an Israeli company, has started final-stage tests of its oral insulin. The product has entered phase three trials under the US Food and Drug Administration. If successful, Oramed expects to make the product available to type 2 diabetics in just over three years, followed by type 1 diabetics after further testing. The company aims to improve the lives of diabetics worldwide and reduce the cost of treatment. Oramed has received a $50 million licensing and investment deal from China’s Hefei Life Science & Technology Park Investments and Development Co. for the rights to its oral insulin capsule in China. The oral insulin is designed to be delivered directly to the liver, minimizing side effects and potentially replacing injections for some patients.
Customers
growth-positive
Oramed Initiates Phase 3 Trial of Oral Insulin
Oramed Pharmaceuticals has announced the screening of the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes. The trials will evaluate the efficacy and safety of ORMD-0801 in treating T2D patients with inadequate glycemic control. The primary endpoint of the study is to compare the efficacy of ORMD-0801 to placebo in improving glycemic control. Oramed is proud to lead the field in reaching this significant diabetes treatment milestone.
Customers
growth-positive
Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be Featured on Biotalknology Webinar "Oral Delivery of Therapeutic Proteins - Oramed Story" on November 18, 2020
Oramed Pharmaceuticals Inc. announced that Nobel Laureate Prof. Avram Hershko and Oramed Chief Scientific Officer Dr. Miriam Kidron will join Premas Biotechs Co-Founder and Managing Director Dr. Prabuddha Kundu and Co-Founder and Chief Operating Officer Dr. Nupur Mehrotra in a webinar on the oral delivery of therapeutic proteins. The webinar will focus on Orameds progress in the oral delivery of proteins and peptides, particularly its oral insulin ORMD-0801 which is entering Phase 3 trials. Oramed is a platform technology pioneer in oral drug delivery solutions and is seeking to revolutionize the treatment of diabetes with its proprietary lead candidate, ORMD-0801.
Partners
growth-positive
Oramed Issues Shareholder Update on Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted to FDA
Oramed Pharmaceuticals has submitted protocols for its upcoming pivotal Phase 3 studies for its oral insulin candidate, ORMD-0801, based on guidance received from the FDA. The studies will involve about 1,125 patients with type 2 diabetes and will evaluate the safety and efficacy of ORMD-0801 over a treatment period of 6 to 12 months. The company plans to conduct two Phase 3 studies concurrently, recruiting a geographically diverse patient population from multiple sites in the US, European Union countries, and Israel. Patient enrollment is expected to begin in the current quarter, and if the studies are successful, Oramed plans to conduct a pre-BLA meeting and submit a Biologics License Application. Oramed aims to revolutionize the treatment of diabetes with its oral insulin technology.
CustomersInvestment
growth-positive
Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin
Oramed Pharmaceuticals received positive feedback from the FDA during its End of Phase 2 meeting for its oral insulin product. The FDA outlined expectations for the design of Phase 3 trials and the submission of a Biologics License Application (BLA). Oramed plans to conduct two Phase 3 trials concurrently. If successful, the BLA would grant 12 years of marketing exclusivity for the oral insulin product. Oramed believes its product will address unmet needs among people with diabetes. The company is a pioneer in oral delivery solutions for drugs currently delivered via injection and is also developing an oral GLP-1 analog capsule. Oramed has completed multiple Phase 2 clinical trials and is seeking to revolutionize the treatment of diabetes.
Investment
growth-positive
Oramed Patent in Canada Allowed for Oral Delivery of Proteins
Oramed Pharmaceuticals has announced that the Canadian Patent Office intends to grant the company a patent for its invention related to oral administration of proteins. Oramed is a clinical-stage pharmaceutical company focused on developing oral drug delivery systems. The company is seeking to revolutionize diabetes treatment with its lead candidate, ORMD-0801, an oral insulin capsule. Oramed has completed multiple Phase II clinical trials and is also developing an oral GLP-1 analog capsule. The announcement of the patent grant is a growth-positive development for the company. No specific partners, customers, or financial details are mentioned in the article.
Partners
growth-positive
Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million
Oramed Pharmaceuticals Inc. has announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a price of $4.00 per share. The gross proceeds from the offering are expected to be $21 million. The company plans to use the net proceeds for its anticipated Phase 3 clinical trial in ORMD-0801 (Oral Insulin) and for other clinical trials, research and development activities, and general corporate purposes. The offering is expected to close on or about March 2, 2020.
Investment
growth-positive
BRIEF-Oramed Reports Positive Results In The Final Cohort Of Its Phase 2B Oral Insulin Trial
Oramed Pharmaceuticals Inc reported positive results in the final cohort of its Phase 2B oral insulin trial. The results confirmed significant clinical benefits of ORMD-0801 at lower dose treatment.
Customers
growth-negative
Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference
The article contains forward-looking statements from Oramed, a company revolutionizing the treatment of diabetes with its products. The statements discuss the progress, timing, cost, and results of clinical trials and product development programs, as well as the challenges of obtaining regulatory approval and patent protection. The company also mentions competition from other pharmaceutical or biotechnology companies and the need for additional funding. The article emphasizes the risks and uncertainties associated with these factors. The impact on the company is classified as growth-negative. The key theme of the article is forward-looking statements. The structured issues include investment and partners. No specific investors or partners are mentioned. The date of the event described in the article is not provided. The confidence level is 7.
InvestmentPartners
growth-negative
Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801
The article contains forward-looking statements from Oramed, a company that is developing an oral insulin capsule for the treatment of Type 2 diabetes. The statements discuss the potential of their product and the expected timing of release for the Phase IIb trial. However, the article also mentions factors and uncertainties that could impact the companys results, including the progress of clinical trials, regulatory approval, competition, and funding. The article does not mention any specific partners, customers, valuation amount, acquisition amount, layoffs, or investment amount. The date of the event described in the article is not provided.
Investment
growth-positive
Oramed Announces Closing of $18.1 Million Registered Direct Offering
Oramed Pharmaceuticals has closed a registered direct offering, raising $18.1 million from the sale of shares of common stock and warrants. The offering was made to healthcare-focused institutional investors. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. Oramed Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems.
Investment
growth-positive
https://www.jpost.com/Israel-News/Fighting-the-global-diabetes-epidemic-with-Israeli-innovation-571808#/
Oramed Pharmaceuticals, an Israeli medical technology company, has developed an innovative oral insulin capsule that is currently in advanced clinical trials. The capsule aims to transform injectable treatments into oral therapies for both Type 1 and Type 2 diabetes. Orameds CEO, Nadav Kidron, believes that their product can help hundreds of millions of people worldwide. The company has also signed licensing and investment agreements worth up to $50 million with Chinese investment and incubation company HTIT for exclusive rights to market the insulin capsules in China, Hong Kong, and Macau. Additionally, DarioHealth Corp., based in Caesarea, has developed a pocket-sized blood glucose monitoring system and a smartphone application for self-administered diabetes management. The platform provides real-time data and personalized assistance for users.
CustomersPartners
growth-positive
Oramed to Present at the H.C. Wainwright Global Investment Conference
Oramed Pharmaceuticals Inc. will participate in the H.C. Wainwright 20th Annual Global Investment Conference. The CEO will present a corporate overview at the conference.
Investment
growth-positive
Oramed Granted Japanese Patent for GLP-1 Analog Capsule - Oramed Pharmaceuticals
Oramed Pharmaceuticals has been granted a patent for its oral glucagon-like peptide-1 (GLP-1) analog. The company is focused on the development of oral drug delivery systems, particularly for drugs currently delivered via injection. Oramed is seeking to revolutionize diabetes treatment with its proprietary products, including an orally ingestible insulin capsule and an oral GLP-1 analog capsule. The company has completed multiple Phase II clinical trials and is working towards FDA submissions. This patent grant from the Japanese Intellectual Property Office is a positive development for Orameds growth in the field of oral drug delivery.
Investment
growth-positive
Oramed Raises $18.1M For Breakthrough Oral Insulin Capsule
Israeli clinical-stage pharmaceutical company Oramed has raised $18.1 million through a registered direct offering with several healthcare-related investors. The funds will be used for clinical trials. Oramed is known for its orally ingestible insulin capsule and Protein Oral Delivery technology.
Investment
growth-positive
Oramed says oral insulin succeeds in midstage type 2 diabetes trial
Oramed Pharmaceuticals announced positive results from a midstage trial of its experimental oral insulin, ORMD-0801. The drug successfully reduced night-time blood glucose in patients with type 2 diabetes. The results surprised skeptics who doubted the effectiveness of oral insulin. Oramed plans to conduct a larger Phase III trial before seeking approval for the drug. The 28-day Phase II trial involved 180 patients and showed a mean night-time glucose reduction of nearly 6.5 percent compared to a placebo. No serious adverse side effects or issues with hypoglycemia were reported. An oral insulin product, if approved, is expected to be a multibillion-dollar product.
Customers
growth-positive
Oramed to dual list on TASE
Oramed Pharmaceuticals has received authorization for dual listing of its shares on the Tel Aviv Stock Exchange (TASE), in addition to Nasdaq. The companys share price on Nasdaq has risen 32% this year, pushing its market cap up to $110 million. Oramed is the fourth Israeli biomed company to opt for dual listing. The biggest investment in Oramed was $50 million in 2015 by two Chinese investors: China National Pharmaceutical Group Corporation (Sinopharm) and Hefei Life Science & Technology Park Investments.
Public Trading
growth-positive
Oramed Announces Dual-Listing on Tel Aviv Stock Exchange
Oramed Pharmaceuticals has received approval to dual-list its common stock on the Tel Aviv Stock Exchange (TASE). The companys common stock will commence trading on the TASE on July 12, 2017. Oramed believes that dual-listing on the TASE will provide benefits such as an expanded investor pool, eligibility for inclusion in Israels index funds, and expanded trading days and hours. The companys CEO, Nadav Kidron, expects these factors to contribute to superior trading, liquidity, and valuation for Oramed stock.
Public Trading
growth-positive
Oramed to Present at the American Diabetes Association 77th Scientific Sessions - Oramed Pharmaceuticals
Oramed Pharmaceuticals announced that a scientific abstract summarizing the recent Phase IIb study of its orally ingestible insulin capsule, ORMD-0801, will be presented at the ADA 77th Scientific Sessions. The company is focused on the development of oral drug delivery systems and aims to revolutionize the treatment of diabetes. Oramed has completed multiple Phase II clinical trials and is seeking regulatory approval for its products. The ADA Scientific Sessions provide an opportunity for researchers and healthcare professionals to share ideas and learn about advances in diabetes research, treatment, and care. Orameds proprietary flagship product, ORMD-0801, is an orally ingestible insulin capsule.
InvestmentCustomers
http://www.oramed.com/oramed-receives-additional-4-million-milestone-payment-from-htit-2/
growth-positive
Oramed inks huge $50m deal with Chinese pharma firm
Israeli pharma firm Oramed signed a licensing and investment deal with China’s HLST for the rights to its oral insulin capsule. The deal is worth $50 million in total, with an immediate payment of $11 million and an additional payment of $27 million next year. HLST will also pay a 10% royalty on net sales of pills produced based on Oramed’s technology. In return, HLST will receive over a million shares of Oramed common stock. The deal is considered important for both Oramed and Israel, as China is highly interested in Israeli med tech and biotech. The need for a diabetes treatment in China is significant, with millions of people affected by the disease.
PartnersInvestment
growth-positive
Israeli co Oramed to raise $50m from Chinese investors
Oramed Pharmaceuticals Inc. has signed a non-binding letter of intent for a $50 million investment from two Chinese concerns, Sinopharm Capital Management and Hefei Life Science & Technology Park Investments and Development Co. The investors will receive 10% of the company and an exclusive license to market its product in China. They will also be responsible for financing the products approval, setting up a manufacturing plant, and marketing in China. Orameds market cap is $80 million. The companys share price has increased by 19% since the announcement of the potential licensing deal with a different Chinese investment group, Wuzhou. Oramed is currently in Phase IIb trials of its leading product and has $25 million in the bank.
Investment
growth-positive
Oramed signs $50m oral insulin deal with Chinese co
Oramed Pharmaceuticals has signed a $38 million licensing agreement with Chinas Hefei Life Science & Technology Park Investments and Development Co. Ltd. The agreement gives Hefei exclusive rights to market Orameds oral insulin capsule in China, Hong Kong, and Macau. In addition, Hefei is investing $12 million in Oramed. The licensing agreement includes payments of $11 million in near term installments and $27 million upon achievement of certain milestones. Oramed will issue shares to Hefei as part of the investment. Orameds oral insulin capsule is currently in a Phase IIb clinical trial in the US. Oramed believes the agreement will have a significant impact on its future revenues and earnings.
PartnersInvestment
Oramed Pharmaceuticals Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 15 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
Oramed Pharmaceuticals Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 513976712 |
| Crunchbase | oramed-pharmaceuticals |
| Phone | +97225660001 |
| Creator | Rebecca Mack |
| Creator email | rebeccamack26@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-08-24T00:00:00.000Z |
| Created | 2014-07-28T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Public on NASDAQ on Apr, 2006<br>Public on TASE on Jul, 2017<br> |